LGNDLigand Pharmaceuticals Incorporated

$4B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M-40.8% YoY

Gross Profit

$38M75.3% margin

Operating Income

$9M17.3% margin

Net Income

-$895,000-1.8% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+37.3%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$5M

Stock-Based Comp.

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$274M

Stockholders' Equity

$802M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$85M	-40.8%
Gross Profit	$38M	$54M	-30.2%
Operating Income	$9M	$46M	-81.1%
Net Income	-$895,000	$31M	-102.9%

Revenue Segments

Material Sales, Captisol

$30M26%

Material Sales, Captisol, COVID

$26M23%

Royalty

$18M16%

Contract Revenue

$10M9%

Kyprolis

$7M6%

Teriparatide Injection

$6M5%

Contract Revenue, Service

$5M5%

Material Sales, Captisol, Core

$3M3%

Evomela

$2M2%

Rylaze

$2M2%

License Fees

$2M1%

License Fees, Milestones, and Product, Other, Product, Other

$2M1%

Milestone

$1M1%

Royalty, Other

$619,0001%